INBX
Price:
$14.925
Market Cap:
$216.05M
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothe...[Read more]
Industry
Biotechnology
IPO Date
2024-06-04
Stock Exchange
NASDAQ
Ticker
INBX
According to Inhibrx Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 1.45%. This represents a change of -8027.54% compared to the average of -18.29% of the last 4 quarters.
The mean historical ROE of Inhibrx Biosciences, Inc. over the last ten years is -99.41%. The current 1.45% ROE has changed -1558.66% with respect to the historical average. Over the past ten years (40 quarters), INBX's ROE was at its highest in in the June 2024 quarter at 846.99%. The ROE was at its lowest in in the March 2024 quarter at -680.41%.
Average
-99.41%
Median
-23.08%
Minimum
-554.81%
Maximum
89.42%
Discovering the peaks and valleys of Inhibrx Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 121.80%
Maximum Annual ROE = 89.42%
Minimum Annual Increase = -282.44%
Minimum Annual ROE = -554.81%
Year | ROE | Change |
---|---|---|
2023 | -554.81% | 121.80% |
2022 | -250.14% | 60.25% |
2021 | -156.10% | 55.76% |
2020 | -100.22% | -282.44% |
2019 | 54.93% | 1.61% |
2018 | 54.06% | -20.00% |
2017 | 67.57% | -24.43% |
The current ROE of Inhibrx Biosciences, Inc. (INBX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-320.35%
5-year avg
-201.27%
10-year avg
-99.41%
Inhibrx Biosciences, Inc.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Merus N.V. (-45.38%), greater than Lyell Immunopharma, Inc. (-34.64%), greater than Kronos Bio, Inc. (-64.55%), less than Opthea Limited (398.06%), greater than Mineralys Therapeutics, Inc. (-55.92%), less than Eliem Therapeutics, Inc. (0%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-62.66%), greater than Enliven Therapeutics, Inc. (-29.46%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%), less than Protagonist Therapeutics, Inc. (34.68%), less than DICE Therapeutics, Inc. (56.07%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Viridian Therapeutics, Inc. (-45.47%),
Company | ROE | Market cap |
---|---|---|
-36.12% | $5.25B | |
-45.38% | $2.99B | |
-34.64% | $262.95M | |
-64.55% | $64.56M | |
398.06% | $561.68M | |
-55.92% | $663.42M | |
0% | $342.68M | |
-184.40% | $40.46M | |
-35.28% | $223.97M | |
-62.66% | $476.00M | |
-29.46% | $1.19B | |
-62.68% | $626.65M | |
-18.01% | $368.60M | |
-58.83% | $82.44M | |
-39.59% | $80.59M | |
-54.45% | $728.83M | |
34.68% | $2.41B | |
56.07% | $2.27B | |
-35.87% | $431.33M | |
-45.47% | $1.55B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Inhibrx Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Inhibrx Biosciences, Inc.'s ROE?
How is the ROE calculated for Inhibrx Biosciences, Inc. (INBX)?
What is the highest ROE for Inhibrx Biosciences, Inc. (INBX)?
What is the 3-year average ROE for Inhibrx Biosciences, Inc. (INBX)?
What is the 5-year average ROE for Inhibrx Biosciences, Inc. (INBX)?
How does the current ROE for Inhibrx Biosciences, Inc. (INBX) compare to its historical average?